Ethics Institute, Dartmouth College (AD) and Cardiology Section Dartmouth Hitchcock Medical Center and the Geisel School of Medicine at Dartmouth (AVK), Lebanon, NH 03756-0001, USA.
Prog Cardiovasc Dis. 2012 Nov-Dec;55(3):316-20. doi: 10.1016/j.pcad.2012.10.008.
The past fifty years has witnessed dramatic progress in the understanding and treatment of patients suffering from cardiovascular disease leading to symptomatic relief and impressive increases in longevity. These advances have been due in large part to the development, study and implementation of new technology. Within interventional cardiology in particular, these advances have been driven by the availability of new technology in the form of medical devices. Successful device development efforts require close collaboration among basic scientist, clinician-inventors/entrepreneurs, clinician-investigators and corporations. Though the role of the clinician is central to this process, these activities present important conflicts-of-interest (COIs). The purpose of this paper is to 1) characterize these conflicts, 2) provide a context from which to approach their management and 3) recommend management strategies.
在过去的五十年中，心血管疾病患者的理解和治疗取得了显著进展，为症状缓解和寿命显著延长带来了希望。这些进展在很大程度上要归功于新技术的开发、研究和应用。特别是在介入心脏病学领域，这些进展是由医疗器械形式的新技术的可用性所驱动的。成功的设备开发工作需要基础科学家、临床医生发明家/企业家、临床医生研究者和公司之间的密切合作。尽管临床医生的角色是这一过程的核心，但这些活动带来了重要的利益冲突（COIs）。本文的目的是：1）描述这些冲突，2）提供一个管理这些冲突的背景，3）推荐管理策略。
